Ruffin, Ayana T. http://orcid.org/0000-0002-5837-5871
Li, Housaiyin
Vujanovic, Lazar http://orcid.org/0000-0003-1729-8619
Zandberg, Dan P.
Ferris, Robert L. http://orcid.org/0000-0001-6605-2071
Bruno, Tullia C.
Article History
Accepted: 18 October 2022
First Online: 1 December 2022
Competing interests
: L.V. is a co-inventor of a methodology licensed to INmune Bio, Inc., where soluble TNF sequestration using DN-TNF can be used to prevent or treat malignancies. D.P.Z. declares competing interests with Blueprint Medicines (advisory board), Macrogenics (consulting), Prelude Therapeutics (advisory board), and Merck (advisory board) and research support (institutional) from Merck, BMS, AstraZeneca, GlaxoSmithKline, Aduro, Astellas, Macrogenics, Lilly, Bicara, Checkmate Pharma, and Novasenta. R.L.F. declares competing interests with Aduro Biotech, Inc. (consulting), AstraZeneca/MedImmune (clinical trial, research funding), Bristol-Myers Squibb (advisory board, clinical trial, research funding), EMD Serono (advisory board), MacroGenics Inc. (advisory board), Merck (advisory board, clinical trial), Novasenta (consulting, stock, research funding), Numab Therapeutics AG (advisory board), Pfizer (advisory board), Sanofi (consultant), Tesaro (research funding) and Zymeworks Inc. (consultant). T.C.B. declares competing interests with Walking Fish Therapeutics (Scientific Advisory Board). The other authors declare no competing interests.